<DOC>
	<DOCNO>NCT03023111</DOCNO>
	<brief_summary>Cutaneous leishmaniasis ( CL ) standard treatment do parenteral pentavalent antimony ( Sbv ) dose 15-20mg / kg per day 20 day . However , therapeutic failure describe 50 % patient , long period 60 90 day require healing ulcerated lesion indicate need alternative drug . Currently alternative include parenteral drug pentamidine amphotericin B , whose use limit either toxicity , Sbv , parenteral route hinders adherence regularity treatment rural area . Recent study group indicate oral miltefosine effective drug treatment patient CL cause L. ( V. ) guyanensis L. ( V. ) braziliensis Brazil , cure rate 71.4 % 75 % respectively . CL pathogenesis associate intense inflammatory infiltrate tissue damage . Previous trial associate GM-CSF Sbv improved cure rate CL cause L. ( V. ) braziliensis . The objective trial evaluate therapeutic response use miltefosine associate GM-CSF treatment CL cause L. ( V. ) braziliensis endemic region Bahia Cear√° , L. ( V. ) guyanensis Amazon region .</brief_summary>
	<brief_title>Miltefosine GM-CSF Cutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>1 . Untreated ulcerative cutaneous leishmaniasis , laboratory diagnosis obtain least one follow test : direct examination lesion , positive culture PCR Leishmania . 2 . Age : 18 65 year ; 3 . Sex : male female patient ; 4 . Presence least 1 ulcerated lesion location ; 5 . Presence maximum 3 ulcerated lesion ; 6 . Diameter lesion vary 1 5 cm ; 7 . Clinical evolution disease le 1 month 3 month . 1 . Evidence severe underlying disease ( cardiac , renal , hepatic , pulmonary ) malignant disease ; 2 . Patients immunodeficiency HIV carrier ; 3 . Serious protein / caloric malnutrition ; 4 . Active uncontrolled infectiouscontagious disease tuberculosis , leprosy , systemic fungal disease ( histoplasmosis , paracoccidioidomycosis ) similar condition ; 5 . Women pregnant breastfeeding ; 6 . Allergy Sbv miltefosine ; 7 . Previous treatment leishmaniasis ; 8 . Lack capacity willingness provide inform consent ( patient / parent / legal representative ) ; Absence availability visit comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>cytokine</keyword>
	<keyword>treatment</keyword>
</DOC>